Basic and clinical considerations of heparins. Part IHARENBERG, Job.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, issn 0094-6176, 97 p.Conference Proceedings

Heparin in patients with venous thromboembolism and contraindications to oral anticoagulant therapyMONREAL, M.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 69-75, issn 0094-6176Conference Paper

Monoclonal antibodies against heparin and heparinoidsHUHLE, G; HARENBERG, J; MALSCH, R et al.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 17-22, issn 0094-6176Conference Paper

Heterogeneity of unfractionated heparins studied in connection with species, source, and production processesBIANCHINI, P; LIVERANI, L; MASCELLANI, G et al.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 3-10, issn 0094-6176Conference Paper

Measurement of fluorescent-labeled LMM-heparin in biological fluids using protamine-linked microbeadsMALSCH, R; MELUI, D; PIAZOLO, L et al.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 23-30, issn 0094-6176Conference Paper

Identification of candidates for prevention of venous thromboembolismGENSINI, G. F; PRISCO, D; FALCIANI, M et al.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 55-67, issn 0094-6176Conference Paper

Capillary electrophoresis of r-hirudin and a polyethylene glycol derivative of r-hirudin (PEG-hirudin)MALSCH, R; TIMMERMANN, A; HARENBERG, J et al.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 39-43, issn 0094-6176Conference Paper

Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosisHARENBERG, J; STEHLE, G; BLAUTH, M et al.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 83-90, issn 0094-6176Conference Paper

Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis : Rationale and clinical resultsCROWTHER, M; HIRSH, J.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 77-81, issn 0094-6176Conference Paper

Pharmacokinetic properties of LMW-heparin-tyramine fractions with high or low affinity to antithrombin III in the ratSTEHLE, G; WUNDER, A; SINN, H et al.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 31-37, issn 0094-6176Conference Paper

Prevention of recurrences after deep venous thrombosis : Role of low-molecular-weight heparinsPINI, M.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 51-54, issn 0094-6176Conference Paper

Heparins, low-molecular-weight heparins, and other glycosaminoglycans analyzed by agarose gel electrophoresis and azure A-silver stainingLIANCHUN, W; MALSCH, R; HARENBERG, J et al.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 11-16, issn 0094-6176Conference Paper

Treatment of deep vein thrombosis with low-molecular-weight heparins : A consensus statement of the Gesellschaft für Thrombose-und Hämostaseforschung (GTH)HARENBERG, J; SCHMITZ-HUEBNER, U; BREDDIN, K. H et al.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 91-96, issn 0094-6176Conference Paper

Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administrationCELLA, G; CIPRIANI, A; TOMMASINI, A et al.Seminars in thrombosis and hemostasis. 1997, Vol 23, Num 1, pp 45-49, issn 0094-6176Conference Paper